Spark Therapeutics (ONCE) Upgraded at Credit Suisse Group

Credit Suisse Group upgraded shares of Spark Therapeutics (NASDAQ:ONCE) from an underperform rating to a neutral rating in a research note released on Friday, MarketBeat reports. They currently have $44.00 price target on the biotechnology company’s stock, down from their previous price target of $48.00.

ONCE has been the topic of a number of other research reports. Guggenheim began coverage on shares of Spark Therapeutics in a report on Tuesday, October 9th. They set a buy rating and a $70.00 price objective on the stock. Chardan Capital raised their price objective on shares of Spark Therapeutics from $60.00 to $85.00 and gave the stock a neutral rating in a report on Wednesday, August 8th. Zacks Investment Research cut shares of Spark Therapeutics from a hold rating to a sell rating in a report on Thursday, November 8th. Royal Bank of Canada cut their price objective on shares of Spark Therapeutics to $64.00 and set a sector perform rating on the stock in a report on Wednesday, August 8th. Finally, SunTrust Banks cut their price objective on shares of Spark Therapeutics to $61.00 and set a buy rating on the stock in a report on Wednesday, August 8th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and twelve have given a buy rating to the company. The stock has an average rating of Hold and a consensus price target of $65.95.

Spark Therapeutics stock traded up $0.17 during trading on Friday, reaching $39.17. The stock had a trading volume of 872,192 shares, compared to its average volume of 620,973. The company has a quick ratio of 10.36, a current ratio of 10.71 and a debt-to-equity ratio of 0.09. Spark Therapeutics has a 52-week low of $37.33 and a 52-week high of $96.59. The company has a market capitalization of $1.54 billion, a P/E ratio of -5.13 and a beta of 2.27.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.22). Spark Therapeutics had a negative return on equity of 14.18% and a negative net margin of 127.82%. The company had revenue of $10.70 million for the quarter, compared to analyst estimates of $27.44 million. During the same period in the previous year, the business posted ($1.90) EPS. The firm’s revenue for the quarter was up 463.2% compared to the same quarter last year. As a group, research analysts anticipate that Spark Therapeutics will post -1.44 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Spark Therapeutics in the 3rd quarter valued at $122,000. Bank of Montreal Can increased its holdings in shares of Spark Therapeutics by 1,045.4% in the 3rd quarter. Bank of Montreal Can now owns 3,253 shares of the biotechnology company’s stock valued at $177,000 after acquiring an additional 2,969 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of Spark Therapeutics in the 2nd quarter valued at $203,000. Shell Asset Management Co. acquired a new position in shares of Spark Therapeutics in the 3rd quarter valued at $208,000. Finally, Smith Asset Management Group LP increased its holdings in shares of Spark Therapeutics by 39.6% in the 3rd quarter. Smith Asset Management Group LP now owns 3,950 shares of the biotechnology company’s stock valued at $215,000 after acquiring an additional 1,120 shares during the period.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Featured Article: Dividend

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply